Payment overview · 2025
General Payments
$198,057.08
299 reported records · 40 companies
Healthcare provider profile · identity verified
Conan Tu, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · MASSAPEQUA, NY · NPI 1083794440
Verified facts
What the public records show
CMS Open Payments records show Conan Tu, M.D. received $198,057.08 in general payments during 2025 across 299 reported records.
SANOFI-AVENTIS U.S. LLC accounted for 52.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 62 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Auvelity, Entresto, Farxiga, Jardiance, Kerendia, Mounjaro, Ozempic, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Farxiga by this doctor in 2024.
Axsome Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Auvelity as an associated drug or biological on 116023 records involving 35298 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Auvelity by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Jardiance by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNJARDY as an associated drug or biological on 33 records involving 33 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Synjardy by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 321 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 157 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Rybelsus by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SOLIQUA 100/33 as an associated drug or biological on 43 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Soliqua 100-33 by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $104,384.13 | 52.7% | 76 | 2025 |
| SANOFI US SERVICES INC. | Unresolved — no canonical attribution shown | $25,403.06 | 12.8% | 5 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $22,629.94 | 11.4% | 9 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $20,413.88 | 10.3% | 35 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $13,408.63 | 6.8% | 23 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $4,060.06 | 2.0% | 7 | 2025 |
| Madrigal Pharmaceuticals | Unresolved — no canonical attribution shown | $2,023.95 | 1.0% | 7 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $839.84 | 0.4% | 11 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $605.04 | 0.3% | 9 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $568.71 | 0.3% | 16 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $506.30 | 0.3% | 7 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $384.93 | 0.2% | 19 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $325.35 | 0.2% | 6 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $306.82 | 0.1% | 7 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $300.93 | 0.1% | 7 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $280.25 | 0.1% | 7 | 2025 |
| BETA BIONICS, INC. | Unresolved — no canonical attribution shown | $259.84 | 0.1% | 6 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $228.37 | 0.1% | 2 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$155.63 | 0.1% | 3 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $148.39 | 0.1% | 1 | 2025 |
| RECORDATI_RARE_DISEASES_INC. | Unresolved — no canonical attribution shown | $97.44 | 0.1% | 4 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $88.71 | 0.0% | 5 | 2025 |
| Tandem Diabetes Care, Inc. | Unresolved — no canonical attribution shown | $87.25 | 0.0% | 3 | 2025 |
| Ascendis Pharma Endocrinology Inc | Unresolved — no canonical attribution shown | $68.35 | 0.0% | 3 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $66.37 | 0.0% | 3 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $53.67 | 0.0% | 2 | 2025 |
| Renalytix AI, Inc. | Unresolved — no canonical attribution shown | $45.28 | 0.0% | 2 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $36.33 | 0.0% | 1 | 2025 |
| MEDICOMP INC | Unresolved — no canonical attribution shown | $33.50 | 0.0% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $31.93 | 0.0% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $29.13 | 0.0% | 1 | 2025 |
| Averitas Pharma Inc. | Unresolved — no canonical attribution shown | $25.71 | 0.0% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $24.74 | 0.0% | 1 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $23.22 | 0.0% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $23.20 | 0.0% | 1 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $22.07 | 0.0% | 1 | 2025 |
| InSightec,Inc | Unresolved — no canonical attribution shown | $19.74 | 0.0% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $19.30 | 0.0% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $14.26 | 0.0% | 1 | 2025 |
| Spinal Elements, INC. | Unresolved — no canonical attribution shown | $12.83 | 0.0% | 2 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $92,272.50 | 23 |
| Consulting Fee | $60,399.25 | 16 |
| Travel and Lodging | $26,329.17 | 43 |
| Food and Beverage | $12,056.16 | 210 |
| Compensation for serving as faculty or as a speaker for a medical education program | $7,000.00 | 7 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TZIELD Normalized: tzield |
Biological | GENZYME CORPORATION, SANOFI US SERVICES INC., SANOFI-AVENTIS U.S. LLC | $134,281.20 | 84 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $20,413.88 | 35 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $11,720.01 | 11 | 2025 |
Source payment records
|
|||||
| OMNIPOD Normalized: omnipod |
Device | Insulet Corporation | $4,060.06 | 7 | 2025 |
Source payment records
|
|||||
| REZDIFFRA Normalized: rezdiffra |
Drug | Madrigal Pharmaceuticals | $2,023.95 | 7 | 2025 |
Source payment records
|
|||||
| Victoza Normalized: victoza |
Drug | Novo Nordisk Inc | $930.00 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $519.63 | 5 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $519.19 | 13 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $472.75 | 9 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $325.35 | 6 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $306.82 | 7 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $288.64 | 6 | 2025 |
Source payment records
|
|||||
| iLet Bionic Pancreas Normalized: ilet bionic pancreas |
Device | BETA BIONICS, INC. | $259.84 | 6 | 2025 |
Source payment records
|
|||||
| iLet Insulin Infusion Kit Contact Detach Normalized: ilet insulin infusion kit contact detach |
Device | BETA BIONICS, INC. | $259.84 | 6 | 2025 |
Source payment records
|
|||||
| iLet Insulin Infusion Kit Inset Normalized: ilet insulin infusion kit inset |
Device | BETA BIONICS, INC. | $259.84 | 6 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $257.41 | 2 | 2025 |
Source payment records
|
|||||
| OFEV Normalized: ofev |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $250.00 | 2 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $228.37 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $226.76 | 5 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $191.12 | 5 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $184.30 | 11 | 2025 |
Source payment records
|
|||||
| FASENRA Normalized: fasenra |
Biological | AstraZeneca Pharmaceuticals LP | $181.11 | 4 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $175.60 | 7 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $159.52 | 4 | 2025 |
Source payment records
|
|||||
| MINIMED 780G Normalized: minimed 780g |
Device | Medtronic, Inc. | $155.63 | 3 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $148.39 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $138.70 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $138.70 | 1 | 2025 |
Source payment records
|
|||||
| ISTURISA Normalized: isturisa |
Drug | RECORDATI_RARE_DISEASES_INC. | $97.44 | 4 | 2025 |
Source payment records
|
|||||
| t:slim X2 Insulin Pump with Control-IQ Normalized: t slim x2 insulin pump with control iq |
Device | Tandem Diabetes Care, Inc. | $87.25 | 3 | 2025 |
Source payment records
|
|||||
| RECORLEV Normalized: recorlev |
Drug | Xeris Pharmaceuticals, Inc. | $85.41 | 4 | 2025 |
Source payment records
|
|||||
| Yorvipath Normalized: yorvipath |
Drug | Ascendis Pharma Endocrinology Inc | $68.35 | 3 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $62.84 | 4 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $59.85 | 3 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $58.49 | 4 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $58.49 | 4 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $54.30 | 8 | 2025 |
Source payment records
|
|||||
| UNITHROID Normalized: unithroid |
Drug | Amneal Pharmaceuticals LLC | $53.67 | 2 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $53.49 | 2 | 2025 |
Source payment records
|
|||||
| KIDNEYINTELX BLOOD COLLECTION CONVENIENCE KIT Normalized: kidneyintelx blood collection convenience kit |
Device | Renalytix AI, Inc. | $45.28 | 2 | 2025 |
Source payment records
|
|||||
| COSENTYX Normalized: cosentyx |
Drug | Novartis Pharmaceuticals Corporation | $39.64 | 2 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $36.33 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $33.66 | 2 | 2025 |
Source payment records
|
|||||
| TELEPATCH CARDIAC MONITOR Normalized: telepatch cardiac monitor |
Device | MEDICOMP INC | $33.50 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $31.93 | 1 | 2025 |
Source payment records
|
|||||
| RINVOQ Normalized: rinvoq |
Biological | ABBVIE INC. | $29.13 | 1 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $26.73 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $26.73 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $25.87 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $25.87 | 1 | 2025 |
Source payment records
|
|||||
| M-M-R II Normalized: m m r ii |
Biological | Merck Sharp & Dohme LLC | $25.87 | 1 | 2025 |
Source payment records
|
|||||
| QUTENZA Normalized: qutenza |
Drug | Averitas Pharma Inc. | $25.71 | 1 | 2025 |
Source payment records
|
|||||
| TEPEZZA Normalized: tepezza |
Biological | Amgen Inc. | $25.03 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $24.74 | 1 | 2025 |
Source payment records
|
|||||
| CRENESSITY Normalized: crenessity |
Drug | Neurocrine BioSciences, Inc. | $23.22 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $23.20 | 1 | 2025 |
Source payment records
|
|||||
| AMVUTTRA Normalized: amvuttra |
Drug | Alnylam Pharmaceuticals Inc. | $22.07 | 1 | 2025 |
Source payment records
|
|||||
| Exablate Normalized: exablate |
Device | InSightec,Inc | $19.74 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $19.30 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $14.26 | 1 | 2025 |
Source payment records
|
|||||
| Medical Device Normalized: medical device |
Device | Spinal Elements, INC. | $12.83 | 2 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $12.29 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Auvelity auvelity |
2025 | Auvelity | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ENTRESTO entresto |
2025 | Entresto | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 77 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 45 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 56 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 321 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 157 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 59 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
42 | 12 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
77 | 24 |
| Axsome Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | Auvelity open payments reported associated product |
CMS Open Payments — General Payments 116023 supporting records · 35298 recipient NPIs · example record 1235293064 |
Auvelity · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
56 | 13 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
45 | 15 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | SYNJARDY open payments reported associated product |
CMS Open Payments — General Payments 33 supporting records · 33 recipient NPIs · example record 1222725005 |
Synjardy · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
45 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
321 | 59 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
52 | 19 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
157 | 35 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
59 | 17 |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | SOLIQUA 100/33 open payments reported associated product |
CMS Open Payments — General Payments 43 supporting records · 15 recipient NPIs · example record 1233224976 |
Soliqua 100-33 · 2024 Exact normalized brand match · 1 Part D row |
39 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Mounjaro | Tirzepatide | 321 | 59 |
| Atorvastatin Calcium | Atorvastatin Calcium | 186 | 81 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 165 | 66 |
| Ozempic | Semaglutide | 157 | 35 |
| Levothyroxine Sodium | Levothyroxine Sodium | 122 | 45 |
| Amlodipine Besylate | Amlodipine Besylate | 106 | 50 |
| Metformin Hcl Er | Metformin Hcl | 83 | 38 |
| Metoprolol Succinate | Metoprolol Succinate | 78 | 31 |
| Farxiga | Dapagliflozin Propanediol | 77 | 24 |
| Metformin Hcl | Metformin Hcl | 75 | 33 |
| Losartan Potassium | Losartan Potassium | 65 | 32 |
| Rybelsus | Semaglutide | 59 | 17 |
| Kerendia | Finerenone | 56 | 13 |
| Lisinopril | Lisinopril | 53 | 23 |
| Trulicity | Dulaglutide | 52 | 19 |
| Simvastatin | Simvastatin | 51 | 20 |
| Hydrochlorothiazide | Hydrochlorothiazide | 47 | 20 |
| Fluoxetine Hcl | Fluoxetine Hcl | 46 | 19 |
| Jardiance | Empagliflozin | 45 | 15 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 45 | 20 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 42 | 16 |
| Synthroid | Levothyroxine Sodium | 42 | 12 |
| Pantoprazole Sodium | Pantoprazole Sodium | 40 | 17 |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 39 | 14 |
| Azelastine Hcl | Azelastine Hcl | 37 | 21 |
| Fluticasone Propionate | Fluticasone Propionate | 37 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 37 | 16 |
| Meclizine Hcl | Meclizine Hcl | 36 | 12 |
| Novolog Flexpen | Insulin Aspart | 36 | 12 |
| Gabapentin | Gabapentin | 31 | 15 |
| Allopurinol | Allopurinol | 29 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 29 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 28 | 17 |
| Famotidine | Famotidine | 27 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 25 | 12 |
| Furosemide | Furosemide | 25 | 11 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 24 | suppressed |
| Omeprazole | Omeprazole | 24 | 11 |
| Trazodone Hcl | Trazodone Hcl | 24 | 12 |
| Alprazolam | Alprazolam | 23 | 13 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 22 | 13 |
| Bupropion Xl | Bupropion Hcl | 22 | 12 |
| Synjardy | Empagliflozin/Metformin Hcl | 22 | suppressed |
| Ezetimibe | Ezetimibe | 21 | suppressed |
| Glimepiride | Glimepiride | 21 | suppressed |
| Dutasteride | Dutasteride | 20 | suppressed |
| Nystatin | Nystatin | 20 | suppressed |
| Xarelto | Rivaroxaban | 20 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 19 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 18 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 18 | suppressed |
| Ramipril | Ramipril | 18 | suppressed |
| Repatha Sureclick | Evolocumab | 18 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 18 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 17 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 17 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 17 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Valsartan | Valsartan | 17 | suppressed |
| Potassium Chloride | Potassium Chloride | 16 | suppressed |
| Auvelity | Dextromethorphan Hbr/Bupropion | 15 | suppressed |
| Carvedilol | Carvedilol | 14 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 14 | suppressed |
| Entresto | Sacubitril/Valsartan | 14 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 14 | suppressed |
| Omnipod 5 Dexg7g6 Pods (Gen 5) | Insulin Pump Cart,auto,bt,g6/7 | 14 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 13 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 12 | suppressed |
| Bumetanide | Bumetanide | 12 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 12 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 12 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 12 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 12 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 12 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 11 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 11 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 11 | 11 |
| Vascepa | Icosapent Ethyl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $198,057.08 · 299 records | SANOFI-AVENTIS U.S. LLC | ABRYSVO, AIRSUPRA, AMVUTTRA, Auvelity, BREZTRI, CAPVAXIVE, COMIRNATY, COSENTYX, CRENESSITY, Cologuard Collection Kit, Dexcom G6 Transmitter, ENTRESTO, EVENITY, Exablate, FARXIGA, FASENRA, FREESTYLE LIBRE 3, GARDASIL 9, GVOKE HYPOPEN, INSPIRE, ISTURISA, JARDIANCE, KIDNEYINTELX BLOOD COLLECTION CONVENIENCE KIT, Kerendia, Korlym, LEQVIO, Leqembi, M-M-R II, MINIMED 780G, MOUNJARO, Medical Device, OFEV, OMNIPOD, OTEZLA, Ozempic, PAXLOVID, PREVNAR 20, PROLIA, QUTENZA, RECORLEV, REPATHA, REZDIFFRA, RINVOQ, Rybelsus, SPRAVATO, Symbravo, TELEPATCH CARDIAC MONITOR, TEPEZZA, TRELEGY ELLIPTA, TZIELD, UNITHROID, VERQUVO, Veozah, Victoza, WATCHMAN FLX, Wegovy, Yorvipath, ZEPBOUND, iLet Bionic Pancreas, iLet Insulin Infusion Kit Contact Detach, iLet Insulin Infusion Kit Inset, t:slim X2 Insulin Pump with Control-IQ | 14 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Auvelity play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error